Summit Therapeutics annual total assets
2019
2020
2021
2022
2023
2024
2025
Summit Therapeutics Total Assets Growth & History (SMMT)
Summit Therapeutics's total assets was $751.2M for fiscal 2025.
View full Summit Therapeutics company overviewSummit Therapeutics annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $751.2M | $315.6M | +72.46% |
| 2024 | 2024-12-31 | $435.6M | $232.6M | +114.62% |
| 2023 | 2023-12-31 | $202.9M | −$461.2M | −69.44% |
| 2022 | 2022-12-31 | $664.2M | $550.8M | +485.82% |
| 2021 | 2021-12-31 | $113.4M | $10.9M | +10.61% |
| 2020 | 2020-12-31 | $102.5M | $6.3M | +6.49% |
| 2019 | 2019-12-31 | $96.2M | — | — |
Summit Therapeutics quarterly total assets
Q4.19
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $752.2M | $428.1M | +132.13% |
| Q1 2026 | 2026-03-31 | $647.9M | $264.0M | +68.79% |
| Q4 2025 | 2025-12-31 | $751.2M | $315.6M | +72.46% |
| Q3 2025 | 2025-09-30 | $261.7M | −$241.1M | −47.95% |
| Q2 2025 | 2025-06-30 | $324.0M | −$17.8M | −5.21% |
| Q1 2025 | 2025-03-31 | $383.8M | $207.0M | +117.12% |
| Q4 2024 | 2024-12-31 | $435.6M | $232.6M | +114.62% |
| Q3 2024 | 2024-09-30 | $502.9M | $284.4M | +130.16% |
| Q2 2024 | 2024-06-30 | $341.9M | $104.5M | +44.02% |
| Q1 2024 | 2024-03-31 | $176.8M | −$78.1M | −30.65% |
| Q4 2023 | 2023-12-31 | $202.9M | −$461.2M | −69.44% |
| Q3 2023 | 2023-09-30 | $218.5M | $63.1M | +40.66% |
| Q2 2023 | 2023-06-30 | $237.4M | $141.7M | +147.99% |
| Q1 2023 | 2023-03-31 | $254.9M | $138.4M | +118.85% |
| Q4 2022 | 2022-12-31 | $664.2M | $550.8M | +485.82% |
| Q3 2022 | 2022-09-30 | $155.3M | $26.7M | +20.71% |
| Q2 2022 | 2022-06-30 | $95.7M | −$49.8M | −34.22% |
| Q1 2022 | 2022-03-31 | $116.5M | −$24.3M | −17.27% |
| Q4 2021 | 2021-12-31 | $113.4M | $10.9M | +10.61% |
| Q3 2021 | 2021-09-30 | $128.7M | $71.8M | +126.28% |
| Q2 2021 | 2021-06-30 | $145.5M | — | — |
| Q1 2021 | 2021-03-31 | $140.8M | — | — |
| Q4 2020 | 2020-12-31 | $102.5M | $6.3M | +6.49% |
| Q3 2020 | 2020-09-30 | $56.9M | — | — |
| Q4 2019 | 2019-12-31 | $96.2M | — | — |
Summit Therapeutics total assets trends
Over the last five fiscal years, Summit Therapeutics's total assets increased from $102.5M to $751.2M, a change of $648.7M. The latest reported quarter, Q2 2026, shows $752.2M.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
SEC-reported total assets
TickerStat uses total assets reported in company SEC filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Summit Therapeutics source filings ↗